期刊文献+

卡培他滨联合奥沙利铂治疗晚期结肠癌的临床疗效观察 被引量:5

Clinical Curative Effect of Xeloda Regimen With Oxaliplatin on Patients With Advanced Colon Cancer
下载PDF
导出
摘要 目的:观察卡培他滨加用奥沙利铂联合治疗晚期结肠癌的临床疗效和毒副作用。方法给予36例晚期结肠癌患者卡培他滨1250 mg/m2日两次口服,第1~14 d,奥沙利铂130 mg/m2,第1 d静滴3 h,21 d为1个疗程周期,2个疗程以上做疗效评价。结果36例均可评价疗效, CR3例,PR18例,RR58.3%;毒副作用主要为恶心、呕吐、腹泻、口腔溃疡、末梢神经异常及骨髓抑制,大多数为Ⅰ~Ⅱ度。结论卡培他滨加用奥沙利铂联合治疗晚期结肠癌临床疗效肯定,且患者耐受性较好。 Objective To observe the clinical efficacy and tolerability of xeloda with oxaliplatin on advanced colon cancer.MethodsThirty-six patients with advanced colon cancer were treated with xeloda 1 250 mg/m2 po on the first day to the 14 day and oxaliplatin 130 mg/m2 ivgtt,on the first 21 days for a period of treatment cycle. More than 2 courses of curative effect were evaluated. Results Thirty-six cases evaluated curative effect,CR 3 cases,19 cases of PR. The overal response rate was 61.1%. Toxicity mainly were grade Ⅰ~Ⅱ,including nausea vomiting,diarrhea,oral ulcer,bone marrow suppression,and peripheral nerve abnormalities.Conclusion Xeloda regimen combined with oxaliplatin into curative effect on treatment of advanced colorectal cancer,and patient tolerance is good.
作者 杜敏娟
出处 《中国卫生标准管理》 2015年第20期102-103,共2页 China Health Standard Management
关键词 卡培他滨 奥沙利铂 晚期结肠癌 联合化疗 Xeloda Oxaliplatin Advanced colon cancer Combination chemotherapy
  • 相关文献

参考文献4

二级参考文献27

  • 1张文,许立功.晚期结直肠癌的化疗进展[J].中国癌症杂志,2004,14(4):378-382. 被引量:25
  • 2杨凯,周绍棠,杨传永.奥沙利铂、顺铂和卡铂抗肿瘤作用的对比性研究[J].腹部外科,2004,17(6):368-369. 被引量:9
  • 3李岩,梁婧,刘文波.卡培他滨联合草酸铂治疗晚期大肠癌的临床观察[J].临床肿瘤学杂志,2005,10(2):180-182. 被引量:12
  • 4张小田.进展期结直肠癌的内科治疗进展[J].癌症进展,2007,5(1):35-40. 被引量:18
  • 5Sakamoto J, Clink, Kondo K, et al. Phase Ⅱ study of a 4-week capecitabineregimen in advanced or recurrent gastric cancer [JJ. Anticancer Drugs, 2006, 17 (2): 231-236.
  • 6Hong YS, Song SY, Lee SI, et al. A phase Ⅱ trail of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer [J]. Ann Oncol, 2004, 15 (9): 1344-1347.
  • 7Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients[ J]. Cancer Chemother Pharmacol, 2000, 45 (4): 291-297.
  • 8Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer [J]. J Clin Oncol, 2004, 22 ( 11): 2084-2091.
  • 9Sakamoto J, Clin K, Kondo K, et al. Phase I1 study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer [J].Anticancer Drugs,2006;17 (2): 231-6.
  • 10Hong YS, Song SY, Lee SI, et al. A phase II trail of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer [J].Ann Oncol, 2004;15(9) : 1344-7.

共引文献56

同被引文献37

引证文献5

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部